Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004232 · ClinicalTrials.gov registry record · Phase 1
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
A Phase 1 study of Lymphoma and Leukemia, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00004232: Completed Phase 1 study of Lymphoma and Leukemia, sponsored by Northwestern University.
NCT00004232 is a Phase 1 study of Lymphoma and Leukemia that has completed, run by Northwestern University. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004232, a Phase 1 study of Lymphoma and Leukemia, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of bone marrow and peripheral stem cell transplantation in treating patients who have hematologic cancer.
Conditions Studied
Interventions
- DRUG prednisone
- DRUG methylprednisolone
- BIOLOGICAL filgrastim
- PROCEDURE allogeneic bone marrow transplantation
- DRUG cyclosporine
Study Locations (1)
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-10 |
| Est. Completion | 2002-10 |
| Phase | Phase 1 |
What the finished NCT00004232 record still lists
NCT00004232 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 7 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which prednisone is the first listed.
NCT00004232 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00004232 about?
NCT00004232 is a clinical study titled "Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer". RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of bone marrow and peripheral stem cell transplantation in treatin...
What is the current status of trial NCT00004232?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-10. Estimated completion is 2002-10.
What conditions does trial NCT00004232 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Plasma Cell Neoplasm, Graft-Versus-Host Disease.
What interventions are being tested in trial NCT00004232?
The interventions under investigation include: prednisone (DRUG), methylprednisolone (DRUG), filgrastim (BIOLOGICAL), allogeneic bone marrow transplantation (PROCEDURE), cyclosporine (DRUG).
Who is sponsoring clinical trial NCT00004232?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004232 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia